Eko Foundation Analysis Software with Transformers (EFAST) vs FFRct
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EFAST by Eko Health provides real-time AI analysis of auscultation data to detect structural murmurs and atrial fibrillation during routine exams. In contrast, HeartFlow FFRct Analysis processes CCTA scans to create personalized 3D models for diagnosing coronary artery disease by assessing blood flow. While both are FDA-cleared cardiology AI tools, they address different cardiac conditions and utilize distinct input modalities and diagnostic approaches.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EFAST by Eko Health is an FDA-cleared AI model designed to assist clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation during routine exams. HeartFlow FFRct Analysis is a non-invasive, AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease.
EFAST utilizes AI during real-time auscultation with Eko digital stethoscopes to analyze heart sounds and ECG data. FFRct uses AI and computational fluid dynamics to create personalized 3D models of coronary arteries from previously acquired CCTA scans to analyze blood flow and identify areas of narrowing.
EFAST is designed for use in Cardiology, Family Medicine, and Internal Medicine. FFRct is primarily intended for Cardiology and Radiology specialties.
EFAST reports 93% sensitivity and 91% specificity for structural murmur detection, and 95% sensitivity and 94% specificity for atrial fibrillation detection. The provided information for FFRct does not include specific sensitivity and specificity metrics, but studies have shown it has high diagnostic performance for vessel-specific ischemia using invasive FFR as the reference standard.
More Comparisons
Backers
Who funded each tool's parent company.